Bristol-Myers Squibb vs Broadcom: Founders, CEOs and History
Bristol-Myers Squibb was founded in 1887 by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers and is led by Christopher Boerner. Broadcom was founded in 1991 by Henry Samueli, Henry Nicholas III and is led by Hock Tan.
Company facts
Bristol-Myers Squibb
- Founded
- 1887
- Headquarters
- Princeton, New Jersey
- Current CEO
- Christopher Boerner
- Employees
- 32,500
Broadcom
- Founded
- 1991
- Headquarters
- Palo Alto, California
- Current CEO
- Hock Tan
- Employees
- 33,000
Founders
Bristol-Myers Squibb
Edward Robinson Squibb
Squibb resigned his Navy post and opened a small laboratory in Brooklyn in 1858 to make pure ether, chloroform and other medicines.
William McLaren Bristol
In 1887 Bristol and Myers bought the Clinton Pharmaceutical Company of Clinton, New York, reportedly for about $5,000.
John Ripley Myers
Myers and Bristol bought the Clinton Pharmaceutical Company in Clinton, New York, in 1887 and renamed it Bristol, Myers and Company in 1898.
Broadcom
Henry Samueli
Henry Samueli co-founded Broadcom Corporation in Los Angeles in 1991 with Henry Nicholas III, his former doctoral student, and served as its chief technical officer while the company built chips for cable modems, set-top boxes, Ethernet and Wi-Fi.
Henry Nicholas III
Henry Nicholas III co-founded Broadcom Corporation with Samueli in 1991 and was its president and CEO through the cable modem boom, the April 1998 IPO and a string of stock-funded acquisitions in 1999 and 2000. He resigned in January 2003.
CEOs and their tenures
Bristol-Myers Squibb
- Charles A. Heimbold Jr.1994–2001
Chief Executive Officer
Serving as CEO from 1994 to 2001, he aggressively expanded the company's oncology portfolio, notably launching the blockbuster cancer drug Taxol, which drove massive revenue growth.
Source - Peter R. Dolan2001–2006
Chief Executive Officer
Dolan, who had run the consumer products and medical device divisions, succeeded Charles Heimbold in May 2001. His tenure included the ImClone partnership on the cancer drug Erbitux and a federal investigation into wholesaler inventory practices.
Source - James M. Cornelius2006–2010
Chief Executive Officer
Cornelius took over after Peter Dolan's removal in September 2006 and ran the company until May 2010.
Source - Lamberto Andreotti2010–2015
Chief Executive Officer
Andreotti, previously president and chief operating officer, became CEO on May 4, 2010.
Source - Giovanni Caforio2015–2023
Chief Executive Officer
Caforio, a physician, succeeded Lamberto Andreotti in May 2015. He led the $74 billion Celgene acquisition in 2019, the $13.1 billion MyoKardia deal in 2020 and the $4.1 billion Turning Point deal in 2022, and agreed the Mirati purchase in October 2023.
Source - Chris Boerner2023–present
Board Chair and Chief Executive Officer
Boerner became CEO in November 2023 and board chair on April 1, 2024, after serving as executive vice president, chief operating officer and CEO-designate from April 2023 and earlier as chief commercialization officer.
Source
Broadcom
- Henry Samueli1991–present
Co-Founder and Chairman of the Board
Henry Samueli co-founded Broadcom Corporation in 1991 and, as chief technical officer, led the engineering behind its cable modem, Ethernet and Wi-Fi chips. He joined the board after Avago bought Broadcom Corporation in 2016 and is chairman of Broadcom Inc.
Source - Henry Nicholas III1991–2003
Co-Founder; President and CEO of Broadcom Corporation
Henry Nicholas III ran Broadcom Corporation from its founding through its April 1998 IPO and the dot-com boom, then resigned in January 2003. Backdating and drug charges brought against him in 2008 were dismissed in December 2009 and January 2010.
Source - Scott McGregor2005–2016
President and CEO of Broadcom Corporation
Scott McGregor led Broadcom Corporation from 2005 until Avago completed its $37 billion acquisition in February 2016, a period when the company expanded in Wi-Fi, Bluetooth, set-top box and data center switch chips.
Source - Hock Tan2006–present
President and Chief Executive Officer
Hock E. Tan became CEO of Avago Technologies in March 2006 and has run the company through its acquisitions of LSI (2014), Broadcom Corporation (2016), Brocade (2017), CA Technologies (2018), Symantec's enterprise business (2019) and VMware (2023).
Source - Kirsten Spears2020–2026
Chief Financial Officer
Kirsten Spears was CFO for about six years of her 12 years at Broadcom, covering the VMware financing and the AI-driven growth of 2024 and 2025. She retired on 12 June 2026 and agreed to advise the company for nine months.
Source - Amie Thuener2026–present
Chief Financial Officer
Amie Thuener joined Broadcom as CFO on 12 June 2026 from Alphabet, where she had been vice president, corporate controller and chief accounting officer since 2018, after an earlier career at PricewaterhouseCoopers.
Source
Timeline: Bristol-Myers Squibb and Broadcom side by side
1858Bristol-Myers Squibb
Edward Robinson Squibb opens his Brooklyn laboratory
Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.
1887Bristol-Myers Squibb
Bristol and Myers buy the Clinton Pharmaceutical Company
Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.
1898Bristol-Myers Squibb
Bristol, Myers and Company is named
The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.
1944Bristol-Myers Squibb
Penicillin at wartime scale
Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.
1989Bristol-Myers Squibb
Bristol-Myers and Squibb merge
Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.
1991Broadcom
Broadcom Corporation founded
UCLA professor Henry Samueli and his former doctoral student Henry Nicholas III found Broadcom Corporation in Los Angeles to build broadband communications chips in CMOS, starting with chips for cable modems and digital set-top boxes.
1998Broadcom
Broadcom Corporation IPO
Broadcom Corporation lists on Nasdaq in April 1998 at $24 a share, as cable operators roll out DOCSIS cable modems built on its chips.
2005Broadcom
Avago Technologies formed
KKR and Silver Lake buy Agilent Technologies' semiconductor products group, whose roots go back to Hewlett-Packard's chip operations, for about $2.66 billion and name it Avago Technologies.
2006Bristol-Myers Squibb
CEO Peter Dolan removed over the Plavix deal
After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.
2006Broadcom
Hock Tan becomes CEO of Avago
Hock Tan becomes president and CEO of Avago in March 2006 and begins pruning its portfolio to the businesses with defensible technology.
2009Bristol-Myers Squibb
Medarex bought and Mead Johnson split off
BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.
2009Broadcom
Avago lists on Nasdaq
Avago Technologies goes public on Nasdaq in August 2009 at $15 a share, giving it stock to use in later acquisitions.
2011Bristol-Myers Squibb
FDA approves Yervoy
Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.
2012Bristol-Myers Squibb
FDA approves Eliquis
The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.
2014Bristol-Myers Squibb
FDA approves Opdivo
The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.
2014Broadcom
LSI Corporation acquired
Avago completes its $6.6 billion purchase of LSI in May 2014, adding storage controllers and custom ASIC design teams.
2016Broadcom
Avago buys Broadcom Corporation
Avago completes its $37 billion acquisition of Broadcom Corporation in February 2016, takes the Broadcom name and trades as AVGO.
2017Broadcom
Brocade acquired
Broadcom completes its $5.9 billion purchase of Brocade Communications in November 2017, adding Fibre Channel storage networking switches.
2018Broadcom
Qualcomm bid blocked and move to the U.S.
President Trump blocks Broadcom's unsolicited bid for Qualcomm on national security grounds in March 2018. Broadcom completes its redomicile from Singapore to the United States that April.
2018Broadcom
CA Technologies acquired
Broadcom completes its $18.9 billion purchase of CA Technologies in November 2018, its first large software deal, creating the infrastructure software segment.
2019Bristol-Myers Squibb
Celgene acquisition closes
BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.
2019Broadcom
Symantec enterprise security acquired
Broadcom buys Symantec's enterprise security business for $10.7 billion in November 2019, adding endpoint, web and data loss prevention software.
2020Bristol-Myers Squibb
MyoKardia deal and a GAAP loss
BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.
2022Bristol-Myers Squibb
Turning Point bought as Revlimid generics arrive
BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.
2022Broadcom
VMware deal announced
Broadcom agrees in May 2022 to buy VMware in a cash-and-stock deal valued at about $61 billion at announcement.
2023Bristol-Myers Squibb
Chris Boerner becomes CEO
Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.
2023Broadcom
VMware acquisition closes
Broadcom completes the VMware acquisition on 22 November 2023 after clearances in the U.S., EU, UK and China, a deal valued at about $69 billion including assumed debt.
2024Bristol-Myers Squibb
Karuna, Mirati and RayzeBio close; Cobenfy approved
The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.
2024Broadcom
Stock split and $1 trillion market value
Broadcom splits its stock 10-for-1 in July 2024, sells VMware's end-user computing unit to KKR for about $4 billion, reports fiscal 2024 revenue of $51.6 billion and passes $1 trillion in market value in December 2024.
2025Bristol-Myers Squibb
BioNTech partnership, Orbital deal and $48.2B revenue
BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.
2025Broadcom
OpenAI partnership and record fiscal 2025
OpenAI and Broadcom agree in October 2025 to deploy 10 gigawatts of OpenAI-designed accelerators. Fiscal 2025 revenue rises 24% to $63.9 billion, with about $20 billion from AI chips.
2026Bristol-Myers Squibb
Guidance raised and merger reports denied
On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.
2026Broadcom
AI chips pass half of revenue
Amie Thuener becomes CFO in June 2026. Third-quarter fiscal 2026 revenue rises 86% to $29.6 billion, and AI semiconductor revenue of $16.7 billion is 56% of the total.
Acquisitions
Bristol-Myers Squibb
- Orbital Therapeutics2025$1.5B
- Mirati Therapeutics2024$4.8B
- RayzeBio2024$4.1B
- Karuna Therapeutics2024$14B
- Turning Point Therapeutics2022$4.1B
- MyoKardia2020$13.1B
Broadcom
- VMware2023$69B
- Symantec Enterprise Security business2019$10.7B
- CA Technologies2018$18.9B
- Brocade Communications Systems2017$5.9B
- Broadcom Corporation2016$37B
- LSI Corporation2014$6.6B
Questions about Bristol-Myers Squibb vs Broadcom
Who is the CEO of Bristol-Myers Squibb Company and Broadcom Inc.?
Bristol-Myers Squibb Company is led by Christopher Boerner and Broadcom Inc. is led by Hock Tan. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Bristol-Myers Squibb Company founded vs Broadcom Inc.?
Bristol-Myers Squibb Company was founded in 1887 — 104 years before Broadcom Inc., which was founded in 1991. Bristol-Myers Squibb Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Broadcom Inc..
How many employees does Bristol-Myers Squibb Company have compared to Broadcom Inc.?
Bristol-Myers Squibb Company employs approximately 32,500 people, while Broadcom Inc. employs approximately 33,000. Broadcom Inc. has the larger workforce at 33,000 employees, compared to Bristol-Myers Squibb Company's 32,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Bristol-Myers Squibb Company and Broadcom Inc. headquartered?
Both Bristol-Myers Squibb Company and Broadcom Inc. are headquartered in United States, meaning they operate under the same primary regulatory and tax environment.
Who founded Bristol-Myers Squibb Company and Broadcom Inc.?
Bristol-Myers Squibb Company was founded by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers. Broadcom Inc. was founded by Henry Samueli, Henry Nicholas III.
Which company has a longer operating history — Bristol-Myers Squibb Company or Broadcom Inc.?
Bristol-Myers Squibb Company has been operating for approximately 139 years, making it the more established of the two companies. Broadcom Inc. has been in operation for around 35 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bristol-Myers Squibb vs Broadcom overview